drugset / Trial / NCT01047540

Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2

NCT01047540

Phase 2 Completed 156 enrolled AiCuris Anti-infective Cures AG FHI 360 · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes

Timeline

Start
2010-03
Primary completion
2010-12
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Pritelivir Small molecule 5 mg Oral
Subject Pritelivir Small molecule 25 mg Oral
Subject Pritelivir Small molecule 75 mg Oral
Subject Pritelivir Small molecule 400 mg Oral